Bordetella bronchiseptica is a potent and safe adjuvant that enhances the antigen-presenting capability of dendritic cells

• Published in: The Korean journal of physiology & pharmacology Vol. 24; no. 1; pp. 47 - 52
• Main Authors: Lee, You-Jeong, Han, Yong, Joo, Hong-Gu
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Physiological Society and The Korean Society of Pharmacology 01.01.2020; 대한약리학회
• Subjects: Original; 약리학; Bordetella bronchiseptica; Immunostimulation; Safety; Vaccines; Dendritic cells
• ISSN: 1226-4512; 2093-3827
• DOI: 10.4196/kjpp.2020.24.1.47

We previously demonstrated that ( ) antigen (Ag) enhances the Ag-specific immune response. The focus of this study was whether acellular bacterin of could be used as an adjuvant to increase antigen-presenting capability of dendritic cells (DCs) by increasing the level of activation. The metabolic activity of DCs was increased by , similar to lipopolysaccharide (LPS). Flow cytometry analysis revealed that increases the expression of major histocompatibility complex class-2, cluster of differentiation (CD)40, CD54, and CD86 which are closely related to DC-mediated immune responses. enhanced the production of cytokines related to adaptive immune responses. Furthermore, the survival rate of -injected groups was 100% at 15 and 20 mg/kg doses, whereas that of LPS-injected groups was only 20%, 0% at 15 and 20 mg/kg doses respectively, and so is likely to be safer than LPS. Taken together, these results indicate that can be used as an adjuvant to enhance the antigen-presenting capability of DCs. is a candidate for producing vaccines, especially in case of DC-mediating efficacy and safety demands. This study provides researchers and clinicians with valuable information regarding the usage of as a safe bacteria-derived immunostimulating agent for developing efficient vaccines.